Join

Compare · ESTA vs EW

ESTA vs EW

Side-by-side comparison of Establishment Labs Holdings Inc. (ESTA) and Edwards Lifesciences Corporation (EW): market cap, price performance, sector, and recent activity on the wire.

Summary

  • Both ESTA and EW operate in Industrial Specialties (Health Care), so they compete in similar markets.
  • EW is the larger of the two at $48.52B, about 24.9x ESTA ($1.95B).
  • Over the past year, ESTA is up 123.8% and EW is up 11.4% - ESTA leads by 112.5 points.
  • ESTA has been more active in the news (7 items in the past 4 weeks vs 5 for EW).
  • EW has more recent analyst coverage (25 ratings vs 13 for ESTA).
PerformanceESTA+123.82%EW+11.37%
2025-04-28+0.00%2026-04-24
MetricESTAEW
Company
Establishment Labs Holdings Inc.
Edwards Lifesciences Corporation
Price
$66.24+1.69%
$84.16+5.54%
Market cap
$1.95B
$48.52B
1M return
+11.16%
+1.83%
1Y return
+123.82%
+11.37%
Industry
Industrial Specialties
Industrial Specialties
Exchange
NASDAQ
NYSE
IPO
2018
News (4w)
7
5
Recent ratings
13
25
ESTA

Establishment Labs Holdings Inc.

Establishment Labs Holdings Inc., a medical technology company, manufactures and markets medical devices for aesthetic and reconstructive plastic surgery. The company primarily offers silicone gel-filled breast implants under Motiva Implants brand. It also provides Divina 3D surgical simulation systems to plastic surgeons for use in pre-surgical patient consultations and planning; and Motiva Flora Tissue Expander, a breast tissue expander, as well as distributes Puregraft line of products for autologous adipose tissue harvesting and redistribution. The company sells its products through exclusive distributors and direct sales force in Europe, Latin America, the Asia-Pacific, and internationally. Establishment Labs Holdings Inc. was incorporated in 2004 and is headquartered in Alajuela, Costa Rica.

EW

Edwards Lifesciences Corporation

Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.